Login to Your Account

Is Gene Therapy Back in Style for VCs? GenSight Lands $42M

By Nuala Moran
Staff Writer

Monday, April 8, 2013

LONDON – Gene therapy start-up GenSight Biologics has raised €32 million (US$41.6 million) in a Series A funding, hinting that following on from the first European regulatory approval of a gene therapy and with an increasing volume of positive clinical data, this iconic field is now de-risked in the eyes of venture capital investors.

The money will fund the ophthalmology specialist until 2016, enabling it to advance two products into Phase II for the treatment of Leber's hereditary optic neuropathy (LHON) and of retinitis pigmentosa.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription